According to a new study led by experts in Dukes Preston Robert Tisch Brain Tumor Middle www.levitrainorge.com.

Celldex Therapeutics vaccine might double survival in patients with deadly brain tumors A vaccine aimed at inducing immunity to the most frequent and deadly type of brain tumor may stave off recurrence and more than dual survival in individuals, according to a new study led by experts in Duke’s Preston Robert Tisch Brain Tumor Middle www.levitrainorge.com . ‘This vaccine represents a very promising therapy for a cancer that comes out of nowhere and robs folks of something the majority of us take for granted – – period,’ said John Sampson, M.D., Ph.D., a neurosurgeon at Duke and lead investigator upon this study. ‘The possibility of doubling anticipated survival – – with few if any unwanted effects – – would represent a big step and a lot of wish for this group of individuals.’ Sampson presented the results of this Phase II study during an oral demonstration at the annual American Culture of Clinical Oncology meeting in Chicago on June 2, 2008.